ABUS
Arbutus Biopharma Corp
5.00$
+0.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 98.5% | 25.8% | 48.1% | 54.6% | 56.7% | 88.9% | 93.2% | 78.6% | 77.3% | 91.4% | 96.7% | 99.8% | |
| 61.1% | 23.4% | 8.5% | 22.9% | 16.2% | 30.1% | 38.1% | 53.4% | 15.7% | 18.2% | 27.6% | 19.0% | |
| 94.9% | 25.5% | 47.3% | 53.3% | 54.7% | 86.1% | 89.9% | 76.0% | 75.2% | 87.3% | 93.1% | 96.7% | |
| 2.1% | 0.2% | 0.1% | 0.2% | 0.6% | 1.1% | 1.0% | 0.4% | 0.7% | 1.2% | 1.8% | 1.8% | |
| 0.0% | 0.1% | 0.0% | 0.0% | – | – | -2.3% | -2.2% | -1.5% | -1.2% | – | – | |
| 1.5% | 0.4% | 2.5% | 5.1% | 4.5% | 8.2% | 5.1% | 2.9% | 2.6% | – | – | – | |
| 0.0% | 22.8% | 8.8% | 10.3% | 9.9% | 0.0% | – | – | – | – | – | – | |
| 0.0% | 49.5% | 36.0% | 24.7% | 19.2% | – | – | – | – | – | – | – | |
| 25.5% | 23.1% | 26.4% | 23.1% | 12.1% | 31.1% | 25.6% | 17.1% | 30.0% | 26.6% | 26.1% | 19.1% | |
| 12.2% | 1.5% | 3.8% | 5.0% | 4.9% | 7.4% | 7.0% | 5.5% | 16.8% | 15.6% | 11.9% | 6.3% | |
| 1.2% | 0.9% | 2.4% | 2.5% | – | 0.3% | 0.3% | 0.2% | 0.2% | 0.3% | 0.4% | 0.6% | |
| 1.7% | 0.4% | 1.2% | 0.8% | 1.4% | 2.3% | 2.2% | 1.6% | 1.8% | 2.2% | 1.8% | 1.2% | |
| 0.0% | 0.0% | 4.3% | 5.1% | – | – | – | – | – | – | – | – | |
| 74.5% | 76.9% | 73.6% | 76.9% | 87.9% | 68.9% | 74.4% | 82.9% | 70.0% | 73.4% | 73.9% | 80.9% | |
| -174.2% | -37.5% | -236.0% | -311.2% | -353.3% | -919.2% | -763.0% | -554.7% | -616.0% | -884.1% | -1,022.4% | -1,458.6% | |
| 19.0% | 6.4% | 19.2% | 23.1% | 24.3% | 54.1% | 55.3% | 52.0% | 77.2% | 114.9% | 140.9% | 202.5% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.